

Bulletin from the extraordinary general meeting in Magle Chemoswed Holding AB

Magle Chemoswed Holding AB ("Magle Group" or the "Company") held an extraordinary general meeting today. The extraordinary general meeting in Magle Group resolved upon the following.

The extraordinary general meeting resolved to approve the board of directors' resolution on an issue of shares with deviation from the shareholders' pre-emption rights. The directed share issue entails that the share capital will increase with up to SEK 44,366.65 through a new share issue of up to 887,333 new shares. Right to subscribe for the new shares shall vest in Hans Henrik Lidgard, Stig Løkke Pedersen and Mats Pettersson who are covered by Chapter 16 in the Swedish Companies Act (2005:551) (the so-called Leo act). The subscription price amounts to SEK 30 per share.

Furthermore, the extraordinary general meeting resolved, in accordance with the shareholder PRS1 ApS' (the "**Shareholder**") proposal, that the number of board members, for the period until the end of the next annual general meeting, shall be six, without any deputy board members, and that Stig Løkke Pedersen be elected as a new board member for the period until the end of the next annual general meeting. The extraordinary general meeting further resolved, in accordance with the Shareholder's proposal, that Stig Løkke Pedersen's remuneration shall amount to SEK 100,000 annually. The remuneration shall be paid proportionately in relation to the duration of the mandate period the board member has held the assignment.

For enquiries, please contact:

Magle Group
Justin Pierce, CEO
Email: justin.pierce@maglechemoswed.com
Telephone: +46 (0)70 593 58 21

About Magle Group

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise, Magle PharmaCept – an established sales and marketing company for development and direct sales of the Group's medical technology products and Magle Biopolymers A/S – a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com, www.maglegroup.com, www.maglepharmaceut.com and www.maglebiopolymers.com.

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

Attachments

[Bulletin from the extraordinary general meeting in Magle Chemoswed Holding AB](#)